7 publications
Name | Date | Type | Actions |
---|---|---|---|
First half 2019 results At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements. |
25/07/2019 | Public releases | |
First half 2018 results At its meeting on July 25, 2018, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2018 financial statements. |
26/07/2018 | Public releases | |
Growth in all financial indicators in 2018. Essentials products sales: €179.4M (up 9.1% at constant exchange rates). Net income group share €36.3M (up 4.0%) At its meeting on March 19, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2018 financial statements. |
20/03/2019 | Public releases | |
Strong growth in all key financial indicators in 2017 ebit up 9.4% to €46.0 million net income - group share up 25.2% to €34.8 million At its meeting on March 14, 2018, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2017 financial statements. |
15/03/2018 | Public releases | |
All key financial indicators up in 2016 At its meeting on March 22, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2016 financial statements. |
22/03/2017 | Public releases | |
Reference products up 6.1% like-for-like in H1 net income group share up 6.5% to €14.4 million At its meeting on July 26, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first half of 2017. |
27/07/2017 | Public releases | |
Vetoquinol acquires Equity Stake in Plant Advanced Technologies PAT Lure and Nancy - November 13, 2017: Vetoquinol, a leading player in the animal health sector, and Plant Advanced Technologies PAT, a plant biotechnology company, announce Vetoquinol’s acquisition of an equity stake in Plant Advanced Technologies PAT. The transaction was carried out via a €500,000 reserved capital increase at a price of €25 per share resulting in the veterinary group holding an equity stake of just over 2% in PAT. |
13/11/2017 | Public releases |